Liposomal bupivacaine ( DrugBank: Bupivacaine )

---

3 diseases

ID	Disease name (Link within this page)	Number of trials
51	Scleroderma	1
70	Spinal stenosis	2
96	Crohn disease	1

51. Scleroderma

---

Clinical trials : 523 /  Drugs : 608 - (DrugBank : 156) / Drug target genes : 114 - Drug target pathways : 215

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02374320 (ClinicalTrials.gov)	November 2014	23/2/2015	Exparel as a Nerve Block for Severe Hand Pain	Chemical Sympathectomy Following Peripheral Nerve Block With Liposomal Bupivacaine	CREST Syndrome;Peripheral Vascular Disease;Raynaud Disease;Scleroderma, Diffuse	Drug: liposomal bupivacaine	Jose Soberon, MD	NULL	Terminated	18 Years	N/A	All	14	Phase 2/Phase 3	United States

70. Spinal stenosis

---

Clinical trials : 96 /  Drugs : 203 - (DrugBank : 60) / Drug target genes : 66 - Drug target pathways : 89

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04066296 (ClinicalTrials.gov)	September 2021	3/7/2019	Outcomes for Lumbar Decompressions With Use of Liposomal Bupivicaine	A Double Blinded Randomized Control Trial in Outcomes for Lumbar Decompressions With Use of Liposomal Bupivicaine	Lumbar Spinal Stenosis	Drug: Liposomal bupivacaine	University of Colorado, Denver	NULL	Not yet recruiting	18 Years	N/A	All	100	Phase 2	NULL
2	NCT03745040 (ClinicalTrials.gov)	January 26, 2019	5/11/2018	Liposomal Bupivacaine in One-level Instrumented Posterior Spinal Fusion	Does Liposomal Bupivacaine Improve Postoperative Pain Control After One Level Posterior Spinal Fusion With Instrumentation	Lumbar Spinal Stenosis;Lumbar Disc Herniation;Lumbar Disc Disease;Lumbar Spondylolisthesis	Drug: Liposomal bupivacaine	Allina Health System	Twin Cities Spine Center	Recruiting	18 Years	N/A	All	60	Phase 4	United States

96. Crohn disease

---

Clinical trials : 2,400 /  Drugs : 1,391 - (DrugBank : 267) / Drug target genes : 170 - Drug target pathways : 215

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03723447 (ClinicalTrials.gov)	October 23, 2018	26/10/2018	Intraoperative TAP Block With Bupivacaine/Dexamethasone Against Liposomal Bupivacaine (Exparel®)	A Prospective Randomized Trial of Transversus Abdominis Plane (TAP) INtraoperative Block With Bupivacaine/Dexamethasone aGainst Liposomal Bupivacaine (Exparel®): the TINGLE Trial	Pain, Postoperative;Crohn Disease;Inflammatory Bowel Diseases;Colorectal Cancer;Gastrointestinal Cancer;Gastrointestinal Disease;Digestive System Disease;Pain;Pain, Neuropathic;Intestinal Disease	Drug: Liposomal bupivacaine;Drug: Bupivacaine/epinephrine/dexamethasone	Cedars-Sinai Medical Center	NULL	Completed	18 Years	90 Years	All	102	Phase 4	United States